Literature DB >> 3046967

Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans.

H Tillil1, E T Shapiro, A H Rubenstein, J A Galloway, K S Polonsky.   

Abstract

Insulin secretion and clearance were studied in eight normal subjects who underwent hyperglycemic clamp studies at plasma glucose levels of 120, 225, and 300 mg/dl on three occasions. Insulin secretion rates were calculated during a 1-h baseline period and during 3 h of glucose clamping from a two-compartmental analysis of peripheral C-peptide concentrations with individual kinetic parameters derived after intravenous bolus injections of biosynthetic human C-peptide. At the 300-mg/dl clamp level, the insulin secretion rate increased to a value 9.9 +/- 0.7 times that of basal at the end of the clamp (mean +/- SE), whereas over the same period, the peripheral insulin concentrations increased to a greater extent, reaching a value 15.4 +/- 1.2 times that of basal (P = .002). This greater relative increase in the insulin concentration in comparison with the corresponding insulin secretion rate suggests a reduction in the clearance of endogenous insulin. A similar trend was seen at the 225-mg/dl clamp level, but the relative increase in the insulin concentration (9.9 +/- 1.5 times that of basal) was not significantly higher than the relative increase in the insulin secretion rate (8.1 +/- 0.5 times that of basal, P = .17). At the 120-mg/dl clamp level, the relative increases in the insulin secretion rate (2.7 +/- 0.2 times that of basal) and the insulin concentration (2.4 +/- 0.2 times that of basal) were similar (P = .26), indicating no reduction in endogenous insulin clearance during moderate stimulation of insulin secretion. In conclusion, a reduction in endogenous insulin clearance occurs during greater stimulation of insulin secretion at higher glucose-clamp levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046967     DOI: 10.2337/diab.37.10.1351

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids.

Authors:  Ximena Lopez; Aaron Cypess; Raquel Manning; Sheila O'Shea; Rohit N Kulkarni; Allison B Goldfine
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin.

Authors:  N Barzilai; P H Groop; L Groop; R A DeFronzo
Journal:  Acta Diabetol       Date:  1995-12       Impact factor: 4.280

3.  Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice.

Authors:  Gina Song; Giovanni Pacini; Bo Ahrén; David Z D'Argenio
Journal:  Peptides       Date:  2016-12-21       Impact factor: 3.750

4.  Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women.

Authors:  F Bonnet; E Disse; M Laville; A Mari; K Hojlund; C H Anderwald; P Piatti; B Balkau
Journal:  Diabetologia       Date:  2012-08-31       Impact factor: 10.122

5.  Influence of exogenous adrenaline on insulin sensitivity under general anesthesia in canine model: a preliminary study.

Authors:  Uno Imaizumi; Takashi Hitosugi; Toshikazu Kobayashi; Kenichi Hirano; Takuji Asano; Yoshihiko Kinoshita; Reiko Yokoyama; Masanori Tsukamoto; Takeshi Yokoyama
Journal:  Hum Cell       Date:  2022-03-15       Impact factor: 4.374

6.  Proportional proinsulin responses in first-degree relatives of patients with type 2 diabetes mellitus.

Authors:  M E Røder; J Eriksson; S G Hartling; L Groop; C Binder
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  β Cell function and plasma insulin clearance in people with obesity and different glycemic status.

Authors:  Bettina Mittendorfer; Bruce W Patterson; Gordon I Smith; Mihoko Yoshino; Samuel Klein
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.